Loading...
Market
How many doses of Pfizer's RSV vaccine ABRYSVO® will be administered to US adults 18-59 by end of 2025?
2
Resolution / Starting Odds
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Public health records and reports from CDC or Pfizer's financial reports
Story
FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for At-Risk Adults 18-59, Addressing Lower Respiratory Tract Disease
Oct 23, 2024, 11:00 AM
The U.S. Food and Drug Administration (FDA) has approved Pfizer's RSV vaccine, ABRYSVO®, for adults aged 18 to 59 who are at increased risk for respiratory syncytial virus (RSV) disease. This approval, announced on October 22, 2024, allows eligible adults to receive the vaccine to prevent lower respiratory tract infections caused by RSV. The approval is seen as a significant step in addressing the health needs of younger adults with chronic conditions who are more vulnerable to RSV. Additionally, the FDA has granted Pfizer a broader label for its RSV vaccine compared to rival vaccines from GlaxoSmithKline (GSK) and Moderna, although the impact on market share remains uncertain.
View original story
Similar markets
Less than 1 million • 25%
1 million to 3 million • 25%
3 million to 5 million • 25%
More than 5 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Decrease by less than 10% • 25%
Decrease by 10% to 20% • 25%
Decrease by 20% to 30% • 25%
Decrease by more than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 1.5 million • 25%
More than 1.5 million • 25%